Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study

References

• Montgomery SA, Nielsen RZ, Poulsen LH, Häggström L. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin–noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Hum Psychopharmacol 2014;29:470-482
   Google Scholar
• Montgomery SA, Baldwin DS, Blier P, et al. Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol 2007;22:323-9
   PubMed Web of Science ®Google Scholar
• Nolen WA, van de Putte JJ, Dijken WA, et al. Treatment strategy in depression. I. Non-tricyclic and selective reuptake inhibitors in resistant depression: a double-blind partial crossover study on the effects of oxaprotiline and fluvoxamine. Acta Psychiatr Scand 1988;78:668-75
   PubMed Web of Science ®Google Scholar
• Nolen WA, Haffmans PM, Bouvy PF, Duivenvoorden HJ. Monoamine oxidase inhibitors in resistant major depression: a double-blind comparison of brofaromine and tranylcypromine in patients resistant to tricyclic antidepressants. J Affect Disord 1993;28:189-97
   PubMed Web of Science ®Google Scholar
• Lenox-Smith AJ, Jiang Q. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor. Int Clin Psychopharmacol 2008;23:113-19
   PubMed Web of Science ®Google Scholar
• Thase ME, Rush AJ. When at first you don’t succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 1997;58(Suppl 13):23-9
   PubMed Web of Science ®Google Scholar
• Alvarez E, Perez V, Dragheim M, et al. A double-blind, randomized, placebo-controlled, active-reference study of Lu AA21004 in patients with major depressive disorder (MDD). Int J Neuropsychopharmacol 2012;15:589-600
   PubMed Web of Science ®Google Scholar
• ICH Harmonised Tripartite Guideline E6: Guideline for Good Clinical Practice, 1996. Available at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073122.pdf [Last accessed 17 December 2014]
   Google Scholar
• World Medical Association (WMA). Declaration of Helsinki: Ethical principles for medical research involving human subjects, 2008. Available at: http://www.wma.net/en/30publications/10policies/b3/ [Last accessed 17 December 2014]
   Google Scholar
• eMC (electronic Medicines Compendium). Summary of Product Characteristics (SmPC): Efexor XL. 2011. Available at: http://www.medicines.org.uk/emc/medicine/2210/SPC/ [Last accessed 17 December 2014]
   Google Scholar
• American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders, 4th edn, Text Revision (DSM-IV-TR). Washington DC: American Psychiatric Association, 2000
   Google Scholar
• Lecrubier Y, Sheehan DV, Weiller E, et al. The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI. Eur Psychiatry 1997;12:224-31
   Web of Science ®Google Scholar
• Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9
   PubMed Web of Science ®Google Scholar
• Guy W, ed. Clinical global impressions. In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. Revised edn. Rockville, MD: National Institute of Mental Health, 1976:217-22
   Google Scholar
• Baldwin DS, Loft H, Dragheim M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 (vortioxetine) in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol 2012;22:482-91
   PubMed Web of Science ®Google Scholar
• Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-5
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol 1996;11(Suppl 3):89-95
   PubMed Web of Science ®Google Scholar
• Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993;29:321-6
   PubMed Web of Science ®Google Scholar
• Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the food and drug administration. PLoS Med 2008;5:e45
   PubMed Web of Science ®Google Scholar
• Melander H, Salmonson T, Abadie E, van Zwieten-Boot B. A regulatory apologia – a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. Eur Neuropsychopharmacol 2008;18:623-7
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Möller HJ. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant? Int Clin Psychopharmacol 2009;24:111-18
   PubMed Web of Science ®Google Scholar
• Poolsup N, Li Wan Po A, Knight TL. Pharmacogenetics and psychopharmacotherapy. J Clin Pharm Ther 2000;25:197-220
   PubMed Web of Science ®Google Scholar
• Hvenegaard MG, Bang-Andersen B, Pedersen H, et al. Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos 2012;40:1357-65
   PubMed Web of Science ®Google Scholar
• Mancama D, Kerwin RW. Role of pharmacogenomics in individualising treatment with SSRIs. CNS Drugs 2003;17:143-51
   PubMed Web of Science ®Google Scholar
• Coleman KA, Xavier VY, Palmer TL, et al. An indirect comparison of the efficacy and safety of desvenlafaxine and venlafaxine using placebo as the common comparator. CNS Spectr 2012;17:131-41
   PubMed Web of Science ®Google Scholar
• Citrome L. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. Int J Clin Pract 2014;68:60-82
   PubMed Web of Science ®Google Scholar